Stopping semaglutide leads to weight regain for most people
[PMC free article: PMC11060317] [PubMed: 38694308] 8
While Ozempic is an injectable prescription drug, its primary compound, semaglutide, is also available in the form of oral tablets (Rybelsus)
Significant vomiting or diarrhoea can lead to dehydration , which may increase the risk of acute kidney injury, particularly in older adults or those taking diuretics or other nephrotoxic medicines
The FDA has also approved Wegovy for adolescents aged 12 years and older who have obesity, defined as: a BMI at or above the 95th percentile for age and sex, based on CDC growth charts Must weigh at least 60 kg (132 lbs) Administered as a once-weekly subcutaneous injection Must be used in conjunction with a reduced-calorie diet and increased physical activity If an adolescent does not achieve at least a 5% reduction in BMI after 12 weeks on the 2.4 mg or maximum tolerated dose, treatment should be discontinued and re-evaluated In March 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, stroke, and heart attack in adults with cardiovascular disease and either obesity or overweight
